Please login to the form below

Not currently logged in
Email:
Password:

orphan drug

This page shows the latest orphan drug news and features for those working in and with pharma, biotech and healthcare.

bluebird bio lodges counterclaim against Spark Therapeutics

bluebird bio lodges counterclaim against Spark Therapeutics

bluebird bio is developing its gene therapy LentiGlobin for sickle cell disease, which currently has an orphan drug designation as well as fast track and rare paediatric disease designations from the ... US Food and Drug Administration (FDA).

Latest news

More from news
Approximately 5 fully matching, plus 253 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 56 partially matching documents found.

Latest appointments

  • New faces at Lucid Group and ZPB Associates New faces at Lucid Group and ZPB Associates

    Most recently, she worked in the consultancy’s rare diseases division, where is provided crisis management support in pricing/access barriers for an orphan drug.

  • Recruiters PIR International appoint four new executives Recruiters PIR International appoint four new executives

    Whilst working with multi-nationals he has assisted US headquartered specialty and orphan drug companies establish their European infrastructure.

  • New hires at Nanoform, Leo Pharma and Calliditas New hires at Nanoform, Leo Pharma and Calliditas

    The combination of his strong experience in regulatory affairs, not only with the FDA but on a broad international basis with a proven track record and experience from orphan drug development ... During his time at Novo Nordisk, he led the strategic

  • Novo Nordisk target Ablynx reshuffles its board Novo Nordisk target Ablynx reshuffles its board

    Dr Hensen’s expertise lies in orphan drug research and development, international marketing and commercialisation and has experience in regulatory, pharmacovigilance, medical marketing and business development knowledge.

  • Dr Irina Antonijevic joins vasopharm Dr Irina Antonijevic joins vasopharm

    In this role, Dr Antonijevic will be responsible for advancing the clinical development of the cerebrovascular specialist's lead orphan drug candidate, VAS203. ... She brings over 15 years of global drug development experience in neuroscience to vasopharm

More from appointments
Approximately 0 fully matching, plus 10 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 13 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Iguazu

Iguazu Ltd is a digital healthcare agency, delivering tactical and innovative solutions. WHAT WE DO We are Closed Loop Marketing...

Latest intelligence

Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
Employee wellbeing in creative agencies: three tips to get you started
Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
Managing unhelpful pressure in your creative agency: the human approach
Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...